ADMA Biologics Announces Commercial Relaunch and
its First Commercial Sales of BIVIGAM®
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy
ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy:READ MOREADMA Biologics Announces Data Presented at IDWeek 2019
ADMA Biologics Announces Data Presented at IDWeek 2019:READ MOREADMA Biologics Announces Poster Presentation at IDWeek 2019
ADMA Biologics Announces Poster Presentation at IDWeek 2019:READ MORE